Viome secures $25M for diagnostic expansion with new COO in Bellevue

Viome has successfully raised $25 million in a Series D funding round aimed at expanding its diagnostic division. This investment will enhance the company's preventative health technologies and solidify its market position. The funding comes from existing backers who express confidence in Viome's innovative approach and growth trajectory, which is reflected in projected year-over-year increases. Kal Raman, a former senior vice president at Amazon and chief digital officer at Samsung, has been appointed as the new Chief Operating Officer to lead these initiatives. Raman's extensive experience in strategic vision and business growth is expected to drive Viome's mission of revolutionizing early disease detection and preventative healthcare. His leadership will focus on launching a suite of new diagnostic tests, including the CancerDetect™ test, which has already set high standards in early cancer detection with impressive sensitivity and specificity rates. The company aims to leverage its FDA Breakthrough Device Designation to accelerate the review process for these innovations. Viome's commitment to making illness optional is central to its operations, and the hiring of Raman aligns with this goal. The company has already empowered over half a million users through its unique approach that combines proprietary RNA sequencing methods with AI technology. This strategy not only optimizes health but also provides insights into aging and wellness. With Raman at the helm, Viome is poised to lead advancements in early disease detection and preventative health, ensuring that individuals can take control of their health through cutting-edge technology and personalized insights. This strategic move marks a significant milestone in Viome's journey towards transforming healthcare.